Seven Fleet Capital Management LP Takes Position in Inhibikase Therapeutics, Inc. $IKT

Seven Fleet Capital Management LP purchased a new position in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 533,648 shares of the company’s stock, valued at approximately $1,094,000. Inhibikase Therapeutics accounts for about 0.8% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 21st biggest position. Seven Fleet Capital Management LP owned approximately 0.71% of Inhibikase Therapeutics at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of IKT. Sands Capital Alternatives LLC grew its holdings in Inhibikase Therapeutics by 18.9% during the fourth quarter. Sands Capital Alternatives LLC now owns 13,018,965 shares of the company’s stock valued at $26,689,000 after purchasing an additional 2,068,965 shares during the period. ADAR1 Capital Management LLC lifted its position in shares of Inhibikase Therapeutics by 53.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after buying an additional 2,816,346 shares during the last quarter. Siren L.L.C. purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at $11,992,000. Commodore Capital LP grew its stake in shares of Inhibikase Therapeutics by 1.0% during the 2nd quarter. Commodore Capital LP now owns 5,397,488 shares of the company’s stock worth $10,525,000 after acquiring an additional 53,056 shares during the period. Finally, Squadron Capital Management LLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter worth $8,661,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Lifesci Capital raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Oppenheimer started coverage on shares of Inhibikase Therapeutics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $5.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Tuesday, April 21st. Finally, LADENBURG THALM/SH SH started coverage on shares of Inhibikase Therapeutics in a research report on Wednesday, March 4th. They issued a “buy” rating and a $4.00 price target on the stock. Four research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $5.40.

Inhibikase Therapeutics Stock Performance

NASDAQ:IKT opened at $1.83 on Friday. Inhibikase Therapeutics, Inc. has a 52-week low of $1.33 and a 52-week high of $2.26. The firm has a market cap of $241.61 million, a price-to-earnings ratio of -4.26 and a beta of 0.92. The business’s fifty day moving average is $1.77 and its 200 day moving average is $1.75.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its earnings results on Tuesday, May 12th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Equities analysts predict that Inhibikase Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.